Hilde Vanaken clearly explained what econsent is, the many different ways it can be carried out and how it is of value to different stakeholders. The system needs to be flexible & interoperable to support different situations.

COVID19 brought the primary care trial team at Oxford to develop a trial with a unique problem which was that participants were unable to travel to their GP practice. To support recruitment they quickly learned the traditional practice was not sufficient or adapted to the circumstances.

After an overview of issues related to paediatric trials and the benefits of DCTs as well as the current overlap, Jaroslaw Meyer-Szary presented MeDMD which looked to identify means of heart failure prevention in patients with Duchenne muscular dystrophy.

The panel included Rachel Copland, Ditte Zerlang Anderson, Ly-Mee Yu, Rafal Staszewski, and addressed a variety of hot topics on the organisation and participation of decentralised clinical trials (DCT). A few key ideas include:

ECRIN's Director General, wrapped up the meeting, covering some of the key information provided by the speakers and sharing key questions that remain to be answered.